WO2004104575A3 - Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2) - Google Patents

Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2) Download PDF

Info

Publication number
WO2004104575A3
WO2004104575A3 PCT/EP2004/005021 EP2004005021W WO2004104575A3 WO 2004104575 A3 WO2004104575 A3 WO 2004104575A3 EP 2004005021 W EP2004005021 W EP 2004005021W WO 2004104575 A3 WO2004104575 A3 WO 2004104575A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
xpnpep2
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/005021
Other languages
French (fr)
Other versions
WO2004104575A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Ralf Thiele
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Ralf Thiele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Ralf Thiele filed Critical Bayer Healthcare Ag
Publication of WO2004104575A2 publication Critical patent/WO2004104575A2/en
Publication of WO2004104575A3 publication Critical patent/WO2004104575A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human XPNPEP2 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, metabolic diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, metabolic diseases, cancer disorders, neurological disorders, respiratory diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of XPNPEP2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/005021 2003-05-23 2004-05-11 Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2) WO2004104575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011704 2003-05-23
EP03011704.8 2003-05-23

Publications (2)

Publication Number Publication Date
WO2004104575A2 WO2004104575A2 (en) 2004-12-02
WO2004104575A3 true WO2004104575A3 (en) 2005-01-27

Family

ID=33462090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005021 WO2004104575A2 (en) 2003-05-23 2004-05-11 Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2)

Country Status (1)

Country Link
WO (1) WO2004104575A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
WO2001000811A2 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. 17867, a novel human aminopeptidase
WO2001089569A1 (en) * 2000-05-23 2001-11-29 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Combinations of enzyme inhibitor-containing preparations and the use thereof
WO2002020736A2 (en) * 2000-09-08 2002-03-14 Incyte Genomics Inc Proteases
US6399349B1 (en) * 1997-09-02 2002-06-04 James W. Ryan Human aminopeptidase P gene
WO2002053170A2 (en) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo
WO2002099379A2 (en) * 2001-06-01 2002-12-12 The Burnham Institute Breast homing peptides and methods of identifying same using aminopeptidase p

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
US6399349B1 (en) * 1997-09-02 2002-06-04 James W. Ryan Human aminopeptidase P gene
WO2001000811A2 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. 17867, a novel human aminopeptidase
WO2001089569A1 (en) * 2000-05-23 2001-11-29 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Combinations of enzyme inhibitor-containing preparations and the use thereof
WO2002020736A2 (en) * 2000-09-08 2002-03-14 Incyte Genomics Inc Proteases
WO2002053170A2 (en) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo
WO2002099379A2 (en) * 2001-06-01 2002-12-12 The Burnham Institute Breast homing peptides and methods of identifying same using aminopeptidase p

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARSHALL PETER ET AL: "Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry.", RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM. 2002, vol. 16, no. 3, 2002, pages 220 - 228, XP002296819, ISSN: 0951-4198 *

Also Published As

Publication number Publication date
WO2004104575A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2005022146A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2004104575A3 (en) Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004097034A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)
WO2005040792A3 (en) Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase